Related Experiment Video
Updated: May 20, 2026

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
Published on: September 8, 2021
[Metabolic syndrome in patients with schizophrenia and antipsychotic treatment]
Eva Aguilar1, Ramón Coronas, Assumpta Caixàs
1Servicio de Psiquiatría, Corporació Sanitària Parc Taulí, Institut Universitari Parc Taulí, Universitat Autònoma de Barcelona, Sabadell, Barcelona, España.
Abstract:
Patients with schizophrenia have a shorter life expectancy and their risk of dying from a cardiovascular disease is higher than the general population. Both facts have been attributed to the raised presence of metabolic syndrome. There is a big amount of scientific publications that deals with the relationship between schizophrenia, antipsychotic treatment, and the development of metabolic syndrome. There is also information about recommendations and clinical guides to achieve an adequate prevention, screening, and treatment of the disease. The aim of this review is to update the current information about this issue and to understand related etiologic factors, differences between antipsychotic drugs, and the current recommendations for patient's care.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Psychosis and Antipsychotic Drugs: Overview
Psychosis: Goals of Pharmacotherapy
Psychological and Sociocultural Causes of Schizophrenia
Drug Therapy
Antianxiety Medications
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
